adobe stock photos - Sergii Figurnyi Final negotiations on proposed EU regulations for plants developed through genetic precision breeding have been delayed, following opposition from a group of MEPs in the European Parliament’s ENVI Committee. The group criticised the European Council and the European Commission for their inflexible stance on issues such as sustainability, labelling, and patent protection.
Laverock TherapeuticsBritish targeted gene silencing specialist Laverock Therapeutics Ltd has expanded its seed funding to £20m by a new financing round led by xx and xx. The company said it will use the funds to…l
Spatial precision in cell analysis is revolutionizing biomedical research. SLACS (Spatially-resolved Laser Activated Cell Sorting) uniquely isolates live microniches within tissues, preserving spatial context and enabling deep biological insights. Its application in organoid research opens vast horizons for disease modeling and therapeutic innovation.
Medicines for EuropeIn a surprise move, Health Commissioner Oliver Várhelyi announced at the Medicines for Europe Annual Conference that the EU Biotech Act will go ahead this year, reversing its provious delay from Q3 2025 to Q3 2026. The legislation has now been fast-tracked because the Commission recognised biotechnology’s rising geostrategic weight.
www.gov.ukThe UK government has unveiled a new industrial strategy that includes a commitment to invest £380m in engineering biology. The package comprises an initial £196m for research and development, and a further £184m for the expansion and modernisation of pilot and scale-up infrastructure.
Customized Enzymes and Reagents from New England Biolabs
MC2 Therapeutics A/SMC2 Therapeutics A/S, a Hørsholm-based pharmaceutical company focused on topical therapies in inflammatory skin conditions, announced the appointment of Trine Ahlgreen as Chief Executive Officer at the end of May.
Max Kratzer / PlectonicUnder a new partnership, Plectonic Biotech will use Sonrai’s AI-powered multi-omics platform to speed up development of its Logybody cancer treatment technology. The approach aims to cut side effects and improve precision.
Alexandros MICHAILIDISThe European Commission has scraped a key piece of Green Deal legislation following political shifts within the European Parliament. The move came after Italy, governed by a far-right administration of Georgia Meloni, aligned itself with the European People’s Party (EPP) on the matter.
Cytiva/Cellular OriginsBritish gene and cell therapy manufacturing specialist Cellular Origins Ltd has entered into a collaboration with Johnson & Johnson to develop a scalable, end-to-end automated platform for autologous CAR-T cell manufacturing.